Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for lung cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Low-dose nivolumab can be effective in non-small cell lungcancer: alternative option for financial toxicity Nivolumab is used at 3 mg/kg or fixed doses of 240 mg every 2 weeks. There was no dose-response/toxicity relationship of nivolumab. This study evaluated the efficacy of low-dose nivolumab as an alternative to the financial toxicity of standard-dose nivolumab in treatment of non-small cell lungcancer (NSCLC).Outcomes of patients with NSCLC treated with nivolumab as a routine practice
CSF-1 and Ang-2 serum levels â€” prognostic and diagnostic partners in non-small cell lungcancerLungcancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1 (...) ) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lungcancer (NSCLC) prognosis and whether these could serve as biomarkers for NSCLC detection, along with Ang-2.We prospectively studied an unselected cohort of 145 patients with NSCLC and a group of 30 control individuals. Serum levels of Ang-2 and CSF-1
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lungcancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lungcancer) This single-arm phase II trial aimed to evaluate a stop-and-go strategy with cisplatin-based chemotherapy and bevacizumab in advanced non-squamous non-small cell lungcancer (NSCLC).Patients were initially treated with three cycles of pemetrexed, cisplatin plus bevacizumab
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lungcancer In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK-positive non-small cell lungcancer. We describe patient-reported outcomes (PROs) from the NP28761 study.PROs (...) and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item EORTC QLQ-lungcancer-specific module) at enrolment and every 6 weeks until week 66, disease progression or death.Clinically meaningful mean improvements (≥10 point change from baseline) were observed in 10 domains, including global health status (GHS), role
Osimertinib (lungcancer) - Addendum to Commission A17-20 1 Translation of addendum A17-47 Osimertinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-20 (Version 1.0; Status: 28 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 28 September 2017 1.0 Commission: A17-47 Version: Status: IQWiG Reports – Commission No. A17-47 (...) Osimertinib (non-small cell lungcancer) – Addendum to Commission A17-20 1 Addendum A17-47 Version 1.0 Osimertinib – Addendum to Commission A17-20 28 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Osimertinib (non-small cell lungcancer) – Addendum to Commission A17-20 Commissioning agency: Federal Joint Committee Commission awarded on: 12 September 2017 Internal Commission No.: A17
Alectinib (non-small-cell lungcancer) - Addendum to commission A17-19 1 Translation of addendum A17-44 Alectinib (nicht kleinzelliges Lungenkarzinom) – Addendum zum Auftrag A17-19 (Version 1.0; Status: 29 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 29 September 2017 1.0 Commission: A17-44 Version: Status: IQWiG Reports – Commission (...) No. A17-44 Alectinib (non-small cell lungcancer) – Addendum to Commission A17-19 1 Addendum A17-44 Version 1.0 Alectinib – Addendum to Commission A17-19 29 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Alectinib (non-small cell lungcancer) – Addendum to Commission A17-19 Commissioning agency: Federal Joint Committee Commission awarded on: 4 September 2017 Internal Commission
Brock malignancy risk calculator for pulmonary nodules: validation outside a lungcancer screening population To assess the performance of the Brock malignancy risk model for pulmonary nodules detected in routine clinical setting.In two academic centres in the Netherlands, we established a list of patients aged ≥40 years who received a chest CT scan between 2004 and 2012, resulting in 16 850 and 23 454 eligible subjects. Subsequent diagnosis of lungcancer until the end of 2014 was established (...) through linking with the National Cancer Registry. A nested case-control study was performed (ratio 1:3). Two observers used semiautomated software to annotate the nodules. The Brock model was separately validated on each data set using ROC analysis and compared with a solely size-based model.After the annotation process the final analysis included 177 malignant and 695 benign nodules for centre A, and 264 malignant and 710 benign nodules for centre B. The full Brock model resulted in areas under
Lungcancer Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4
Atezolizumab (Tecentriq) for non?small cell lungcancer (NSCLC) Published 9 July 2018 1 atezolizumab 1,200mg concentrate for solution for infusion (Tecentriq ® ) SMC No 1336/18 Roche Products Limited 8 June 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the end (...) of life and orphan medicine process atezolizumab (Tecentriq ® ) is accepted for restricted use within NHS Scotland Indication under review: As monotherapy for the treatment of adult patients with locally advanced or metastatic non -small cell lungcancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK) -positive tumour mutations should also have received targeted therapy before receiving atezolizumab. SMC
Palliative thoracic radiotherapy in lungcancer Special Article Palliative thoracic radiation therapy for non- small cell lungcancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline Benjamin Moeller MD, PhD a, ? , Ehsan H. Balagamwala MD b , Aileen Chen MD c , Kimberly M. Creach MD d , Giuseppe Giaccone MD, PhD e , Matthew Koshy MD f , Sandra Zaky MD, MS g , George Rodrigues MD, PhD, FASTRO h a Department of Radiation Oncology, Levine Cancer Institute (...) Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada Received 6 February 2018; accepted 19 February 2018 Abstract Purpose: To revise the recommendation on the use of concurrent chemotherapy (CC) with palliative thoracic external beam radiation therapy (EBRT) made in the original 2011 American Society for Radiation Oncology guideline on palliative thoracic radiation for lungcancer. Methods andmaterials:BasedonasystematicPubMedsearchshowingnewevidenceforthiskey question
Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lungcancer 30035160 2018 11 14 2331-4737 5 5-6 2018 May Oncoscience Oncoscience Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lungcancer. 124-125 10.18632/oncoscience.416 Seguin Laetitia L INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. Féral Chloé C INSERM, U1081, CNRS, UMR7284, Institute (...) for Research on Cancer and Aging of Nice (IRCAN), University of Nice Sophia Antipolis, Nice, France. eng Editorial 2018 06 23 United States Oncoscience 101636666 2331-4737 KRAS galectin-3 integrin lungcancer macropinocytosis CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 03 2018 04 05 2018 7 24 6 0 2018 7 24 6 0 2018 7 24 6 1 epublish 30035160 10.18632/oncoscience.416 416 PMC6049313 Cancer Immunol Res. 2017 Mar;5(3):182-190 28108630 Nat Cell Biol. 2014 May;16(5):457
Feasibility of an eightâ€week outpatientâ€based pulmonary rehabilitation program for advanced lungcancer patients undergoing cytotoxic chemotherapy in Korea The scientific evidence supporting pulmonary rehabilitation (PR) for lungcancer patients undergoing cytotoxic chemotherapy is accumulating; however, the feasibility of outpatient-based PR in these patients has not yet been evaluated in Korea. We conducted an eight-week outpatient-based PR feasibility study in a tertiary referral (...) hospital setting. Patients with advanced lungcancer (non-small cell lungcancer IIIB-IV and small-cell lungcancer extensive disease) scheduled to undergo first-line cytotoxic chemotherapy underwent PR consisting of 60-minute sessions twice a week under the guidance and supervision of a physical therapist, for a total of eight weeks. Feasibility was assessed based on completion of the PR program. In total, 12 patients (median age 68 years) were enrolled; 11 (91.7%) were male with a history of smoking
DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for antiâ€PDâ€1/PDâ€L1 immunotherapy in nonâ€small cell lungcancer 29932513 2019 03 25 2019 03 25 1759-7714 9 8 2018 08 Thoracic cancer Thorac Cancer DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lungcancer. 901-903 10.1111/1759-7714.12785 Zhu Zhongling Z Department of Clinical Pharmacology, Tianjin (...) Medical University Cancer Institute and Hospital, Tianjin, China. National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Chen Peng P National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin, China. Department of Thoracic Medical Oncology, Tianjin LungCancer Center, Tianjin Medical University Cancer Institute
P16 INK4a gene promoter methylation as a biomarker for the diagnosis of nonâ€small cell lungcancer: An updated metaâ€analysis This meta-analysis was conducted to investigate the diagnostic performance of P16INK4a gene promoter methylation as a biomarker of non-small cell lungcancer (NSCLC).Two reviewers independently searched the Web of Science, PubMed, Cochrane, Embase, China National Knowledge Infrastructure, and Chinese Biomedical Literature databases. Publications relevant to P16INK4a (...) gene promoter methylation in serum or bronchoalveolar fluid/sputum were screened and included in this meta-analysis. Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated.Twenty-six publications with 1768 lungcancer cases and 1323 controls were included. The pooled sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio were 0.46 (95% confidence interval [CI] 0.43-0.48), 0.90 (95% CI 0.88-0.91), 6.33
Survival rates after lobectomy versus sublobar resection for earlyâ€stage right middle lobe nonâ€small cell lungcancerLungcancer in the right middle lobe has a poorer prognosis than tumors located in other lobes. The optimal surgical procedure for early-stage non-small cell lungcancer (NSCLC) in the right middle lobe has not yet been elucidated. The aim of this study was to compare survival rates after lobectomy and sublobar resection for early-stage right middle lobe NSCLC.Patients who (...) underwent lobectomy or sublobar resection for stage IA right middle lobe NSCLC tumors ≤ 2 cm between 2004 and 2014 were identified from the Surveillance, Epidemiology and End Results database of 18 registries. Cox regression model analysis was used to evaluate the prognostic factors. The lungcancer-specific survival (LCSS) and overall survival (OS) rates between the two groups were compared.A total of 861 patients met our criteria, including 662 (76.9%) patients who underwent lobectomy and 199 (23.1